Chugai Pharmaceutical Co., Ltd.4519
▲ PositiveCapitalrelevance
Gero's funding and partnership with Chugai may enhance its pipeline, but Chugai is only mentioned as a collaborator, not the subject.
Impact on assets 2
Biotech & Genomic Medicine
Chugai Pharmaceutical Co., Ltd.Health Care
Roche Holding AGROP
Mentioned
Theme Impact 2
Off-coverage companies 2
GeroPrivate▲ Positive
Capitalrelevance
Gero raised $17 million in new financing, bringing total equity to $34 million, supporting preclinical development and partnerships.
Melnichek Investments LtdPrivate± Mixed
relevance
Related news
United Kingdom
Madagascar
Greenland▲
Genflow trial hits endpoint; 80 Mile agrees takeover
Genflow Biosciences announced that its SLAB gene therapy trial in ageing dogs has met its primary endpoint, and it is now in talks with major animal health companies about a licensing deal. EnergyPathways has appointed Jacobs as engineering and regulatory partner for its MESH energy storage project in the Irish Sea, moving toward a key Ofgem funding submission. Itaconix is targeting a doubling of revenue to $30 million in the medium term, after half-year revenue jumped 72% on strong detergent demand. Gaming Realms says it is well placed to keep growing despite a UK tax hike hitting margins, with core content licensing revenue up 12% in the first half. Total Graphite reports that fresh drilling in Madagascar has strengthened the case for restarting mining at Vatomina, with one hole returning 19 metres at 3.3% graphite. 80 Mile has agreed indicative terms for a £61.5 million all-share takeover by Nasdaq-listed Greenland Energy, representing a near-47% premium to its share price.
About megatrends
Longevity & Life Extension › Cellular Reprogramming & Rejuvenation ▲Technology
Critical Materials & Supply Chain › Rare Earths & Permanent Magnets ▲Supply
80M.LSE · Capital · Positive Agreed to a £61.5m all-share takeover by Greenland Energy at a near-47% premium
GENF.LSE · Technology · Positive SLAB gene therapy trial in ageing dogs met its primary endpoint, prompting licensing talks with animal health companies
ITX.LSE · Demand · Positive Half-year revenue jumped 72% on strong detergent demand, targeting $30m medium-term revenue.
GLND · Capital · Positive Agreed indicative terms for a £61.5m all-share takeover of 80 Mile, an M&A event for the acquirer
GMR.LSE · Regulation · Neutral UK tax hike is hitting margins, though core content licensing revenue rose 12% in H1.
EPP.LSE · · Neutral Appointed Jacobs as engineering and regulatory partner for its MESH storage project, moving toward Ofgem funding submission
United StatesInsilico Medicine Launches Virtual Aging Cell Platform
Insilico Medicine has launched its Virtual Aging Cell webpage and previewed a multi-agent driven platform that uses biological age as a core condition for simulating cellular dynamics. The platform deploys agent swarms across six biological scales—molecular, intracellular, intercellular, tissue, organ, and organism—to model differentiation, reprogramming, and aging, aiming to support target identification and drug discovery. The launch follows a decade of work including the PreciousGPT model series, with the company noting it has nominated 33 preclinical candidates since 2021, 13 of which have received IND approvals or clearances. Insilico will present further details at the ARDD 2026 conference in Boston.
About megatrends
Biotech & Genomic Medicine › AI Drug Discovery Technology
Longevity & Life Extension › Cellular Reprogramming & Rejuvenation Technology
Artificial Intelligence › Agentic AI & Autonomous Workflows Technology
Longevity & Life Extension › Longevity Diagnostics & Aging Clocks Technology
3696.HK · Technology · Positive Launch of Virtual Aging Cell platform advances drug discovery capabilities
Life Biosciences appoints Stephen Webster to board of directors
Life Biosciences has appointed Stephen Webster to its board of directors, effective August 1, 2026. Webster is a biotechnology executive who has served as chief financial officer of three public companies and played a key role in multiple financings, commercial launches, and acquisitions. He previously led approximately $1 billion in equity financings at Spark Therapeutics, oversaw its 2015 initial public offering, supported the commercial launch of LUXTURNA, and helped lead the company's $4.3 billion acquisition by Roche. Life Biosciences is a clinical-stage biotechnology company pioneering cellular rejuvenation medicines to reverse diseases of aging, with a lead program in development for optic neuropathies.
About megatrends
Longevity & Life Extension › Cellular Reprogramming & Rejuvenation Talent
Life Biosciences · Capital · Positive Appointment of a seasoned CFO with financing and M&A experience to the board is positive for the company.